Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anneke D van Dijk

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Expert Review of Proteomics|January 17, 2020
Targeted therapy in acute myeloid leukemia: current status and new insights from a proteomic perspectiveAnneke D van Dijk, Eveline S J M de Bont, Steven M Kornblau
Proteomics|March 6, 2018
Histone Modification Patterns Using RPPA-Based Profiling Predict Outcome in Acute Myeloid Leukemia PatientsAnneke D van Dijk, Chenyue W Hu, Eveline S J M de Bont, et al.
Leukemia|October 9, 2021
RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequencesAnneke D van Dijk, Ti'ara L Griffen, Yihua H Qiu, et al.
Proteomics. Clinical Applications|November 1, 2021
Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF-κB subunit RelAAnneke D van Dijk, Fieke W Hoff, Yihua Qiu, et al.
Cancers|April 27, 2024
Chromatin Profiles Are Prognostic of Clinical Response to Bortezomib-Containing Chemotherapy in Pediatric Acute Myeloid Leukemia: Results from the COG AAML1031 TrialAnneke D van Dijk, Fieke W Hoff, Yihua Qiu, et al.
Blood|September 22, 2020
Heat shock factor 1 (HSF1-pSer326) predicts response to bortezomib-containing chemotherapy in pediatric AML: a COG reportFieke W Hoff, Anneke D van Dijk, Yihua Qiu, et al.
Haematologica|January 13, 2022
Clinical relevance of proteomic profiling in <i>de novo</i> pediatric acute myeloid leukemia: a Children's Oncology Group studyFieke W Hoff, Anneke D Van Dijk, Yihua Qiu, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Expert Review of Proteomics|January 17, 2020
Targeted therapy in acute myeloid leukemia: current status and new insights from a proteomic perspectiveAnneke D van Dijk, Eveline S J M de Bont, Steven M Kornblau
Proteomics|March 6, 2018
Histone Modification Patterns Using RPPA-Based Profiling Predict Outcome in Acute Myeloid Leukemia PatientsAnneke D van Dijk, Chenyue W Hu, Eveline S J M de Bont, et al.
Leukemia|October 9, 2021
RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequencesAnneke D van Dijk, Ti'ara L Griffen, Yihua H Qiu, et al.
Proteomics. Clinical Applications|November 1, 2021
Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF-κB subunit RelAAnneke D van Dijk, Fieke W Hoff, Yihua Qiu, et al.
Cancers|April 27, 2024
Chromatin Profiles Are Prognostic of Clinical Response to Bortezomib-Containing Chemotherapy in Pediatric Acute Myeloid Leukemia: Results from the COG AAML1031 TrialAnneke D van Dijk, Fieke W Hoff, Yihua Qiu, et al.
Blood|September 22, 2020
Heat shock factor 1 (HSF1-pSer326) predicts response to bortezomib-containing chemotherapy in pediatric AML: a COG reportFieke W Hoff, Anneke D van Dijk, Yihua Qiu, et al.
Haematologica|January 13, 2022
Clinical relevance of proteomic profiling in <i>de novo</i> pediatric acute myeloid leukemia: a Children's Oncology Group studyFieke W Hoff, Anneke D Van Dijk, Yihua Qiu, et al.
Pageof 1